This is the finding from the REALITY trial, published yesterday in the New England Journal of Medicine.
The REALITY trial looked at ways to reduce deaths in the early stages of treatment. Health economic analysis has found that the enhanced prophylaxis package is cost-effective in all the countries where the trial was carried out.
To read the full article, go to the New England Journal of Medicine website.
Here is the REALITY trial infographic.
The REALITY trial was led by the MRC Clinical Trials Unit at UCL, in collaboration with several clinical sites in Uganda, Zimbabwe, Malawi, Kenya and the London School of Hygiene and Tropical Medicine, UK. The REALITY trial was funded by the Department for International Development, UK (DFID), the Wellcome Trust and the Medical Research Council (MRC) UK. Additional funding support is provided by Fondazione PENTA Onlus. Drugs for the prophylaxis package were donated by Cipla. ARV drugs were donated by Gilead, Viiv, Merck and Cipla.